MA51771A - Procédés de préparation de (1-(3-fluoro-2-(trifluorométhyl)isonicotinyl)pipéridine-4-one) - Google Patents

Procédés de préparation de (1-(3-fluoro-2-(trifluorométhyl)isonicotinyl)pipéridine-4-one)

Info

Publication number
MA51771A
MA51771A MA051771A MA51771A MA51771A MA 51771 A MA51771 A MA 51771A MA 051771 A MA051771 A MA 051771A MA 51771 A MA51771 A MA 51771A MA 51771 A MA51771 A MA 51771A
Authority
MA
Morocco
Prior art keywords
isonicotinyl
piperidine
trifluoromethyl
fluoro
preparation
Prior art date
Application number
MA051771A
Other languages
English (en)
Other versions
MA51771B1 (fr
Inventor
Pingli Liu
Dengjin Wang
Yongzhong Wu
Jiacheng Zhou
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corp filed Critical Incyte Corp
Publication of MA51771A publication Critical patent/MA51771A/fr
Publication of MA51771B1 publication Critical patent/MA51771B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/803—Processes of preparation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
MA51771A 2018-01-30 2019-01-29 Procédés de préparation de (1-(3-fluoro-2-(trifluorométhyl)isonicotinyl)pipéridine-4-one) MA51771B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862623664P 2018-01-30 2018-01-30
PCT/US2019/015582 WO2019152374A1 (fr) 2018-01-30 2019-01-29 Procédés de préparation de (1-(3-fluoro-2-(trifluorométhyl)isonicotinyl)pipéridine-4-one)

Publications (2)

Publication Number Publication Date
MA51771A true MA51771A (fr) 2020-12-09
MA51771B1 MA51771B1 (fr) 2022-03-31

Family

ID=65409599

Family Applications (1)

Application Number Title Priority Date Filing Date
MA51771A MA51771B1 (fr) 2018-01-30 2019-01-29 Procédés de préparation de (1-(3-fluoro-2-(trifluorométhyl)isonicotinyl)pipéridine-4-one)

Country Status (32)

Country Link
US (1) US10899736B2 (fr)
EP (2) EP3746429B1 (fr)
JP (2) JP7393348B2 (fr)
KR (1) KR20200129099A (fr)
CN (1) CN112105608B (fr)
AR (1) AR114810A1 (fr)
AU (1) AU2019213665B2 (fr)
BR (1) BR112020015470A2 (fr)
CA (1) CA3089832A1 (fr)
CL (1) CL2020001983A1 (fr)
CO (1) CO2020009994A2 (fr)
CR (1) CR20200379A (fr)
DK (1) DK3746429T3 (fr)
EA (1) EA202091830A1 (fr)
ES (1) ES2912469T3 (fr)
HR (1) HRP20220510T1 (fr)
IL (1) IL276302B2 (fr)
LT (1) LT3746429T (fr)
MA (1) MA51771B1 (fr)
MD (1) MD3746429T2 (fr)
MX (1) MX2020007973A (fr)
PE (1) PE20211310A1 (fr)
PH (1) PH12020551145A1 (fr)
PL (1) PL3746429T3 (fr)
PT (1) PT3746429T (fr)
RS (1) RS63312B1 (fr)
SG (1) SG11202007164UA (fr)
SI (1) SI3746429T1 (fr)
TW (1) TWI797242B (fr)
UA (1) UA127488C2 (fr)
WO (1) WO2019152374A1 (fr)
ZA (1) ZA202004692B (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3746429B1 (fr) 2018-01-30 2022-03-09 Incyte Corporation Procédés de préparation de (1-(3-fluoro-2-(trifluorométhyl)isonicotinyl)pipéridine-4-one)
BR112020016628A2 (pt) 2018-02-16 2020-12-15 Incyte Corporation Inibidores da via de jak1 para o tratamento de distúrbios relacionados a citocinas
JP2021519772A (ja) 2018-03-30 2021-08-12 インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ 炎症性皮膚疾患のバイオマーカー
CN112567247A (zh) 2018-04-13 2021-03-26 因赛特公司 用于移植物抗宿主病的生物标志物
EP3873433A1 (fr) 2018-10-31 2021-09-08 Incyte Corporation Polythérapie pour le traitement de maladies hématologiques
US11406640B2 (en) 2019-03-05 2022-08-09 Incyte Corporation JAK1 pathway inhibitors for the treatment of chronic lung allograft dysfunction
US11992490B2 (en) 2019-10-16 2024-05-28 Incyte Corporation Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and Lichen planus (LP)
CN110683978A (zh) * 2019-10-30 2020-01-14 西安医学院 一种3-腈基亚甲基氮杂环丁烷-1-碳酸叔丁酯的制备方法
KR20230096973A (ko) 2020-08-18 2023-06-30 인사이트 코포레이션 Jak 저해제를 제조하기 위한 방법 및 중간체
WO2022040172A1 (fr) 2020-08-18 2022-02-24 Incyte Corporation Procédé et intermédiaires pour la préparation d'un inhibiteur de jak1
IL303238A (en) 2020-12-08 2023-07-01 Incyte Corp Jak1 pathway inhibitors for the treatment of vitiligo
CN112625030A (zh) * 2020-12-25 2021-04-09 杭州澳赛诺生物科技有限公司 一种一锅法合成n-保护3-溴代吡唑的合成方法

Family Cites Families (283)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2985589A (en) 1957-05-22 1961-05-23 Universal Oil Prod Co Continuous sorption process employing fixed bed of sorbent and moving inlets and outlets
US3832460A (en) 1971-03-19 1974-08-27 C Kosti Anesthetic-vasoconstrictor-antihistamine composition for the treatment of hypertrophied oral tissue
US4140755A (en) 1976-02-13 1979-02-20 Hoffmann-La Roche Inc. Sustained release tablet formulations
DE3036390A1 (de) 1980-09-26 1982-05-13 Troponwerke GmbH & Co KG, 5000 Köln Neue pyrrolo-pyrimidine, verfahren zu ihrer herstellung und ihre verwendung bei der herstellung von biologischen wirkstoffen
DE3220113A1 (de) 1982-05-28 1983-12-01 Basf Ag, 6700 Ludwigshafen Difluormethoxiphenylthiophosphorsaeureester
US4402832A (en) 1982-08-12 1983-09-06 Uop Inc. High efficiency continuous separation process
US4548990A (en) 1983-08-15 1985-10-22 Ciba-Geigy Corporation Crosslinked, porous polymers for controlled drug delivery
US4498991A (en) 1984-06-18 1985-02-12 Uop Inc. Serial flow continuous separation process
NL8403224A (nl) 1984-10-24 1986-05-16 Oce Andeno Bv Dioxafosforinanen, de bereiding ervan en de toepassing voor het splitsen van optisch actieve verbindingen.
CA1306260C (fr) 1985-10-18 1992-08-11 Shionogi & Co., Ltd. Derives imidazopyridine condenses
DK0495982T3 (da) 1989-10-11 1996-07-01 Teijin Ltd Bicyklisk pyrimidinderivat, fremgangsmåde til fremstilling deraf og farmaceutisk præparat omfattende dette som en aktiv bestanddel
IT1258781B (it) 1992-01-16 1996-02-29 Zambon Spa Composizione farmaceutica oftalmica contenente n-acetilcisteina e polivinilalcol
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
AU671491B2 (en) 1992-12-18 1996-08-29 F. Hoffmann-La Roche Ag N-oxycarbonyl substituted 5'-deoxy-5-fluorcytidines
JPH0710876A (ja) 1993-06-24 1995-01-13 Teijin Ltd ４位に環状アミノ基を有するピロロ［２，３―ｄ］ピリミジン
EP0727217A3 (fr) 1995-02-10 1997-01-15 Suntory Ltd Compositions pharmaceutiques et cosmétiques contenant ellagitannin du type god comme principe actif
US5856326A (en) 1995-03-29 1999-01-05 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
IL117580A0 (en) 1995-03-29 1996-07-23 Merck & Co Inc Inhibitors of farnesyl-protein transferase and pharmaceutical compositions containing them
BR9609613A (pt) 1995-07-05 1999-05-25 Du Pont Composto composição fungicida e método de controle de doenças de plantas
US5630943A (en) 1995-11-30 1997-05-20 Merck Patent Gesellschaft Mit Beschrankter Haftung Discontinuous countercurrent chromatographic process and apparatus
TW531537B (en) 1995-12-27 2003-05-11 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4-substituted piperidine derivatives
GB9604361D0 (en) 1996-02-29 1996-05-01 Pharmacia Spa 4-Substituted pyrrolopyrimidine compounds as tyrosine kinase inhibitors
AU727939B2 (en) 1996-04-03 2001-01-04 Merck & Co., Inc. A method of treating cancer
CA2251955A1 (fr) 1996-04-18 1997-10-23 Nancy E. Kohl Methode de traitement de cancer
US5795909A (en) 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
JP2000508335A (ja) 1996-05-30 2000-07-04 メルク エンド カンパニー インコーポレーテッド 癌の治療方法
US6624138B1 (en) 2001-09-27 2003-09-23 Gp Medical Drug-loaded biological material chemically treated with genipin
CA2286239A1 (fr) 1997-04-07 1998-10-15 Merck & Co., Inc. Procede de traitement du cancer
US6060038A (en) 1997-05-15 2000-05-09 Merck & Co., Inc. Radiolabeled farnesyl-protein transferase inhibitors
US6063284A (en) 1997-05-15 2000-05-16 Em Industries, Inc. Single column closed-loop recycling with periodic intra-profile injection
JP2001513502A (ja) 1997-08-11 2001-09-04 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド ５，６−ヘテロアリールジピリド［２，３−ｂ：３’，２’−ｆ］アゼピン類及びＨＩＶ感染の予防及び治療におけるそれらの使用
US6075056A (en) 1997-10-03 2000-06-13 Penederm, Inc. Antifungal/steroid topical compositions
US6025366A (en) 1998-04-02 2000-02-15 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
US6232320B1 (en) 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
KR20010052570A (ko) 1998-06-04 2001-06-25 스티븐 에프. 웨인스톡 세포 유착을 억제하는 소염성 화합물
PA8474101A1 (es) 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
DE69942097D1 (de) 1998-08-11 2010-04-15 Novartis Ag Isochinoline derivate mit angiogenesis-hemmender wirkung
JP2000119271A (ja) 1998-08-12 2000-04-25 Hokuriku Seiyaku Co Ltd １ｈ―イミダゾピリジン誘導体
ES2190241T3 (es) 1998-09-10 2003-07-16 Nycomed Danmark As Compuestos farmaceuticos de liberacion rapida de substancias medicamentosas.
US6413419B1 (en) 1998-10-29 2002-07-02 Institut Francais Du Petrole Process and device for separation with variable-length chromatographic
FR2785196B1 (fr) 1998-10-29 2000-12-15 Inst Francais Du Petrole Procede et dispositif de separation avec des zones chromatographiques a longueur variable
US6375839B1 (en) 1998-10-29 2002-04-23 Institut Francais Du Petrole Process and device for separation with variable-length chromatographic zones
US6133031A (en) 1999-08-19 2000-10-17 Isis Pharmaceuticals Inc. Antisense inhibition of focal adhesion kinase expression
JP2002538121A (ja) 1999-03-03 2002-11-12 メルク エンド カムパニー インコーポレーテッド プレニルタンパク質トランスフェラーゼの阻害剤
GB9905075D0 (en) 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
US6217895B1 (en) 1999-03-22 2001-04-17 Control Delivery Systems Method for treating and/or preventing retinal diseases with sustained release corticosteroids
US6239113B1 (en) 1999-03-31 2001-05-29 Insite Vision, Incorporated Topical treatment or prevention of ocular infections
WO2000063168A1 (fr) 1999-04-16 2000-10-26 Coelacanth Chemical Corporation Synthese de derives d'azetidine
US6921763B2 (en) 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
EP1221443B1 (fr) 1999-10-13 2004-09-01 Banyu Pharmaceutical Co., Ltd. Derives d'imidazolidinone a substitution
DE60007552T2 (de) 1999-12-10 2004-09-23 Pfizer Products Inc., Groton PYRROLO[2,3-d]PYRIMIDIN-VERBINDUNGEN ALS PROTEIN KINASEN HEMMER
AP1917A (en) 1999-12-24 2008-11-12 Aventis Pharma Ltd Azaindoles
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
US7235551B2 (en) 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
TR200302105T4 (tr) 2000-04-07 2004-02-23 Laboratoire Medidom S. A. Siklosporin, hiyalüronik asit ve polisorbat içeren göz formülasyonları.
WO2001081345A1 (fr) 2000-04-20 2001-11-01 Mitsubishi Pharma Corporation Composes d'amides aromatiques
PT3029041T (pt) 2000-04-25 2020-05-13 Icos Corp Inibidores de fosfatidil-inositol 3-quinase delta humana
JP4954426B2 (ja) 2000-06-16 2012-06-13 キュリス，インコーポレイテッド 血管形成調節組成物及び利用
US7498304B2 (en) 2000-06-16 2009-03-03 Curis, Inc. Angiogenesis-modulating compositions and uses
US6335342B1 (en) 2000-06-19 2002-01-01 Pharmacia & Upjohn S.P.A. Azaindole derivatives, process for their preparation, and their use as antitumor agents
US6930115B2 (en) 2000-06-23 2005-08-16 Mitsubishi Pharma Corporation Antitumor effect potentiators
MXPA03000068A (es) 2000-06-26 2003-09-25 Pfizer Prod Inc Compuestos de pirrolo (2,3-d)pirimidina como agentes inmunosupresores.
CZ303572B6 (cs) 2000-06-28 2012-12-12 Smithkline Beecham P. L. C. Jemne rozmelnený prostredek a zpusob jeho prípravy
US20020111353A1 (en) 2000-12-05 2002-08-15 Mark Ledeboer Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases
GB0100622D0 (en) 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds V111
EP1351936A1 (fr) 2001-01-15 2003-10-15 Glaxo Group Limited Derives aryle de piperidine et de piperazine comme inducteurs de l'expression du recepteur ldl
EP1363702A4 (fr) 2001-01-30 2007-08-22 Cytopia Pty Ltd Procedes d'inhibition de kinases
EP1404669A2 (fr) 2001-05-16 2004-04-07 Vertex Pharmaceuticals Incorporated Inhibiteurs de src et autres proteine kinases
US7301023B2 (en) 2001-05-31 2007-11-27 Pfizer Inc. Chiral salt resolution
GB0115109D0 (en) 2001-06-21 2001-08-15 Aventis Pharma Ltd Chemical compounds
GB0115393D0 (en) 2001-06-23 2001-08-15 Aventis Pharma Ltd Chemical compounds
ES2274986T3 (es) 2001-08-01 2007-06-01 MERCK & CO., INC. Derivados de benzimidazo 4,5-f/isoquinolinona.
JP4456365B2 (ja) 2001-09-19 2010-04-28 アベンティス・ファーマ・ソシエテ・アノニム 化合物
US6429231B1 (en) 2001-09-24 2002-08-06 Bradley Pharmaceuticals, Inc. Compositions containing antimicrobials and urea for the treatment of dermatological disorders and methods for their use
TWI302836B (en) 2001-10-30 2008-11-11 Novartis Ag Staurosporine derivatives as inhibitors of flt3 receptor tyrosine kinase activity
JP2003155285A (ja) 2001-11-19 2003-05-27 Toray Ind Inc 環状含窒素誘導体
EP1460059A4 (fr) 2001-11-30 2005-01-05 Teijin Ltd Procede pour produire un compose d'acide 5-(3-cyanophenyl)-3-formylbenzoique
GT200200234A (es) 2001-12-06 2003-06-27 Compuestos cristalinos novedosos
US6995144B2 (en) 2002-03-14 2006-02-07 Eisai Co., Ltd. Nitrogen containing heterocyclic compounds and medicines containing the same
TW200403058A (en) 2002-04-19 2004-03-01 Bristol Myers Squibb Co Heterocyclo inhibitors of potassium channel function
WO2003091246A1 (fr) 2002-04-26 2003-11-06 Vertex Pharmaceuticals Incorporated Derives de pyrrole utilises en tant qu'inhibiteurs de erk2 et leurs utilisations
CA2483084A1 (fr) 2002-05-02 2003-11-13 Merck & Co., Inc. Inhibiteurs de la tyrosine kinase
MXPA04011004A (es) 2002-05-07 2005-01-25 Control Delivery Sys Inc Procesos para formar un dispositivo de administracion de farmaco.
DE60317198T2 (de) 2002-05-23 2008-12-04 Cytopia Research Pty. Ltd., Richmond Proteinkinaseinhibitoren
TW200406374A (en) 2002-05-29 2004-05-01 Novartis Ag Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases
EP1535934A4 (fr) 2002-06-26 2005-11-02 Idemitsu Kosan Co Copolymere hydrogene, son procede de production et composition d'adhesif thermofusible le contenant
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
GB0215844D0 (en) 2002-07-09 2002-08-14 Novartis Ag Organic compounds
WO2004007472A1 (fr) 2002-07-10 2004-01-22 Ono Pharmaceutical Co., Ltd. Antagoniste du ccr4 et utilisation medicinale correspondante
EP1542768A1 (fr) 2002-09-20 2005-06-22 Alcon, Inc. Utilisation d'inhibiteurs de la synthese des cytokines dans le traitement des troubles associes a la keratoconjonctivite seche
US20040204404A1 (en) 2002-09-30 2004-10-14 Robert Zelle Human N-type calcium channel blockers
CA2506773A1 (fr) 2002-11-04 2004-05-21 Vertex Pharmaceuticals Incorporated Derives d'heteroaryle pyrimidine utilises comme inhibiteurs de jak (janus kinase)
TWI335913B (en) 2002-11-15 2011-01-11 Vertex Pharma Diaminotriazoles useful as inhibitors of protein kinases
US20040099204A1 (en) 2002-11-25 2004-05-27 Nestor John J. Sheet, page, line, position marker
JP2006509000A (ja) 2002-11-26 2006-03-16 ファイザー・プロダクツ・インク 移植片拒絶反応の処置の方法
UA80767C2 (en) 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
TWI335819B (en) 2002-12-24 2011-01-11 Alcon Inc Use of oculosurface selective glucocorticoid in the treatment of dry eye
US7135493B2 (en) 2003-01-13 2006-11-14 Astellas Pharma Inc. HDAC inhibitor
US7444183B2 (en) 2003-02-03 2008-10-28 Enteromedics, Inc. Intraluminal electrode apparatus and method
JP2006518381A (ja) 2003-02-07 2006-08-10 バーテックス　ファーマシューティカルズ　インコーポレイテッド プロテインキナーゼのインヒビターとして有用なヘテロアリール置換ピロール
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
WO2004092154A1 (fr) 2003-04-03 2004-10-28 Vertex Pharmaceuticals Incorporated Compositions utiles en tant qu'inhibiteurs de proteines kinases
SE0301373D0 (sv) 2003-05-09 2003-05-09 Astrazeneca Ab Novel compounds
SE0301372D0 (sv) 2003-05-09 2003-05-09 Astrazeneca Ab Novel compounds
FR2857454B1 (fr) 2003-07-08 2006-08-11 Aventis Pasteur Dosage des acides techoiques des bacteries gram+
US20050043346A1 (en) 2003-08-08 2005-02-24 Pharmacia Italia S.P.A. Pyridylpyrrole derivatives active as kinase inhibitors
JP5010917B2 (ja) 2003-08-29 2012-08-29 エグゼリクシス， インコーポレイテッド ｃ−Ｋｉｔ調節因子および使用方法
WO2005026129A1 (fr) 2003-09-15 2005-03-24 Gpc Biotech Ag Derives d'aminopyrimidine a disubstitution 4,6 actifs sur le plan pharmaceutique en tant que modulateurs des proteine kinases
AR045944A1 (es) 2003-09-24 2005-11-16 Novartis Ag Derivados de isoquinolina 1.4-disustituidas
DK1679074T3 (da) 2003-10-24 2011-03-21 Santen Pharmaceutical Co Ltd Terapeutisk middel til keratoconjunktive forstyrrelser
MY141220A (en) 2003-11-17 2010-03-31 Astrazeneca Ab Pyrazole derivatives as inhibitors of receptor tyrosine kinases
WO2005051393A1 (fr) 2003-11-25 2005-06-09 Pfizer Products Inc. Methode de traitement de l'atherosclerose
AU2004305317A1 (en) 2003-12-17 2005-07-07 Pfizer Products Inc. Pyrrolo [2,3-D] pyrimidine compounds for treating transplant rejection
MXPA06007076A (es) 2003-12-19 2006-08-31 Pharmacopeia Drug Discovery Tiadiazoles como ligandos del receptor cxc y cc-quimiocina.
CN1925855B (zh) 2003-12-19 2010-06-16 普莱希科公司 开发Ret调节剂的化合物和方法
KR101164258B1 (ko) 2003-12-23 2012-07-11 아스텍스 테라퓨틱스 리미티드 단백질 키나아제 조절제로서의 피라졸 유도체
US20050165029A1 (en) 2004-01-13 2005-07-28 Ambit Biosciences Corporation Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases
WO2005089502A2 (fr) 2004-03-18 2005-09-29 The Brigham And Women's Hospital, Inc. Traitement des synucleinopathies
ATE508129T1 (de) 2004-03-30 2011-05-15 Vertex Pharma Als inhibitoren von jak und anderen proteinkinasen geeignete azaindole
CA2563699C (fr) 2004-04-23 2014-03-25 Exelixis, Inc. Modulateurs de kinase et methode d'utilisation
WO2005105988A2 (fr) 2004-04-28 2005-11-10 Vertex Pharmaceuticals Incorporated Structure cristalline de complexe de domaine jak3 kinase humaine et ses poches de liaison
WO2005105814A1 (fr) 2004-04-28 2005-11-10 Incyte Corporation Inhibiteurs tetracycliques de janus kinases
CA2563569A1 (fr) 2004-05-03 2005-11-10 Novartis Ag Combinaisons comprenant un agoniste du recepteur s1p et un inhibiteur de la kinase jak3
MXPA06013250A (es) 2004-05-14 2007-02-28 Abbott Lab Inhibidores de quinasa como agentes terapeuticos.
PE20060426A1 (es) 2004-06-02 2006-06-28 Schering Corp DERIVADOS DE ACIDO TARTARICO COMO INHIBIDORES DE MMPs, ADAMs, TACE Y TNF-alfa
JP4688876B2 (ja) 2004-06-10 2011-05-25 アイアールエム・リミテッド・ライアビリティ・カンパニー タンパク質キナーゼ阻害剤としての化合物および組成物
JP5315611B2 (ja) 2004-06-23 2013-10-16 小野薬品工業株式会社 Ｓ１ｐ受容体結合能を有する化合物およびその用途
EP2325184A1 (fr) 2004-06-30 2011-05-25 Vertex Pharmceuticals Incorporated Azaindoles utilés en tant qu'inhibiteurs des proteine kinases
US7138423B2 (en) 2004-07-20 2006-11-21 Bristol-Myers Squibb Company Arylpyrrolidine derivatives as NK-1 /SSRI antagonists
FR2873691B1 (fr) 2004-07-29 2006-10-06 Sanofi Synthelabo Derives d'amino-piperidine, leur preparation et leur application en therapeutique
WO2006013114A1 (fr) 2004-08-06 2006-02-09 Develogen Aktiengesellschaft Utilisation d'un produit proteique timp-2 secrete pour la prevention et le traitement d'affections du pancreas, de l'obesite et/ou du syndrome metabolique
CN101006186A (zh) 2004-08-23 2007-07-25 财团法人牧岩生命工学研究所 用于检测sars冠状病毒的引物和探针，包括该引物和/或探针的试剂盒及其检测方法
US20070054916A1 (en) 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
CN101039946B (zh) 2004-10-13 2010-12-08 霍夫曼-拉罗奇有限公司 用作用于cdk2和血管生成的抑制剂及用于治疗乳腺、结肠、肺和***癌的二取代吡唑并苯并二氮杂*类
UY29177A1 (es) 2004-10-25 2006-05-31 Astex Therapeutics Ltd Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos
MY179032A (en) 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
JP5030229B2 (ja) 2004-11-04 2012-09-19 バーテックス ファーマシューティカルズ インコーポレイテッド プロテインキナーゼのインヒビターとして有用なピラゾロ［１，５−ａ］ピリミジン
BRPI0517887A (pt) 2004-11-24 2008-10-21 Novartis Ag combinações de inibidores de jaks
US7517870B2 (en) 2004-12-03 2009-04-14 Fondazione Telethon Use of compounds that interfere with the hedgehog signaling pathway for the manufacture of a medicament for preventing, inhibiting, and/or reversing ocular diseases related with ocular neovascularization
WO2006065916A1 (fr) 2004-12-14 2006-06-22 Alcon, Inc. Procede de traitement des troubles associes a la keratoconjonctivite seche par le 13(s)-hode et ses analogues
WO2006067445A2 (fr) 2004-12-22 2006-06-29 Astrazeneca Ab Composes chimiques
AR054416A1 (es) 2004-12-22 2007-06-27 Incyte Corp Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas.
WO2006077499A1 (fr) 2005-01-20 2006-07-27 Pfizer Limited Composes chimiques
CA2596830A1 (fr) 2005-02-03 2006-09-14 Vertex Pharmaceuticals Incorporated Pyrrolopyrimidines utiles en tant qu'inhibiteurs de la proteine kinase
WO2007044050A2 (fr) 2005-02-04 2007-04-19 Bristol-Myers Squibb Company Composés tricycliques basés sur la 1h-imidazo[4,5-d]thiéno[3,2-b]pyridine et préparations pharmaceutiques les incluant
MX2007011316A (es) 2005-03-15 2007-11-12 Irm Llc Compuestos y composiciones como inhibidores de cinasa de proteina.
AU2006232105A1 (en) 2005-04-05 2006-10-12 Pharmacopeia, Inc. Purine and imidazopyridine derivatives for immunosuppression
GB0510139D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B1
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
AU2006251623A1 (en) 2005-05-20 2006-11-30 Vertex Pharmaceuticals Incorporated Pyrrolopyridines useful as inhibitors of protein kinase
KR101312225B1 (ko) 2005-06-08 2013-09-26 리겔 파마슈티칼스, 인크. Ｊａｋ 경로의 억제를 위한 조성물 및 방법
WO2006136823A1 (fr) 2005-06-21 2006-12-28 Astex Therapeutics Limited Amine contenant des heterocycliques comme inhibiteurs des kinases b
CN102206216B (zh) 2005-06-22 2014-11-12 普莱希科公司 作为蛋白质激酶抑制剂的吡咯并[2,3-b]吡啶衍生物
EP2251341A1 (fr) 2005-07-14 2010-11-17 Astellas Pharma Inc. Hétérocycles inhibiteurs de Janus kinase-3
FR2889662B1 (fr) 2005-08-11 2011-01-14 Galderma Res & Dev Emulsion de type huile-dans-eau pour application topique en dermatologie
WO2007025090A2 (fr) 2005-08-25 2007-03-01 Kalypsys, Inc. Inhibiteurs de kinase mapk/erk
CA2621261C (fr) 2005-09-22 2014-05-20 Incyte Corporation Inhibiteurs tetracycliques de janus kinases
NZ567133A (en) 2005-09-30 2011-07-29 Vertex Pharma Deazapurines useful as inhibitors of janus kinases
WO2007044894A2 (fr) 2005-10-11 2007-04-19 Chembridge Research Laboratories, Inc. Systemes d'expression de proteines sans cellules et methodes d'utilisation
US7867949B2 (en) 2005-10-14 2011-01-11 Sumitomo Chemical Company, Limited Hydrazide compound and pesticidal use of the same
DK1939204T6 (da) 2005-10-19 2022-09-05 Kissei Pharmaceutical Kondenseret heterocyklisk derivat, medicinalsammensætning indeholdende samme og medicinsk anvendelse deraf
KR20080063846A (ko) 2005-10-28 2008-07-07 아스트라제네카 아베 암 치료에서 티로신 키나제 억제제로 사용하기 위한4-(3-아미노피라졸)피리미딘 유도체
NZ592990A (en) 2005-11-01 2013-01-25 Targegen Inc Bi-aryl meta-pyrimidine inhibitors of kinases
WO2007062459A1 (fr) 2005-11-29 2007-06-07 Cytopia Research Pty Ltd Inhibiteurs selectifs de la kinase a base d’un squelette de pyridine
US20130137681A1 (en) 2005-12-13 2013-05-30 Incyte Corporation HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS
SI2455382T1 (sl) 2005-12-13 2017-03-31 Incyte Holdings Corporation S heteroarilom substituirani pirolo(2,3b)piridini in pirolo(2,3-b)pirimidini kot zaviralci janus kinaze
WO2007076423A2 (fr) 2005-12-22 2007-07-05 Smithkline Beecham Corporation INHIBITEURS D’ACTIVITE Akt
ES2408318T3 (es) 2005-12-23 2013-06-20 Glaxosmithkline Llc Inhibidores de azaindol de las cinasas Aurora
CA2636189A1 (fr) 2006-01-17 2007-07-26 Vertex Pharmaceuticals Incorporated Azaindoles utiles comme inhibiteurs de janus kinases
CA2635899A1 (fr) 2006-01-19 2007-07-26 Osi Pharmaceuticals, Inc. Inhibiteurs de kinase heterobicycliques fusionnes
WO2007090141A2 (fr) 2006-02-01 2007-08-09 Smithkline Beecham Corporation Composés chimiques
US7745477B2 (en) 2006-02-07 2010-06-29 Hoffman-La Roche Inc. Heteroaryl and benzyl amide compounds
CA2644368A1 (fr) 2006-03-10 2007-09-20 Ono Pharmaceutical Co., Ltd. Derive heterocyclique azote et agent pharmaceutique comprenant le derive en tant que principe actif
WO2007116866A1 (fr) 2006-04-03 2007-10-18 Astellas Pharma Inc. Compose hetero
US8741912B2 (en) 2006-04-05 2014-06-03 Vertex Pharmaceuticals Incorporated Deazapurines useful as inhibitors of Janus kinases
EP2059515A2 (fr) 2006-04-12 2009-05-20 Pfizer Limited Derives de pyrrolidine comme modulateurs de recepteurs ccr5 des chimiokines
WO2007129195A2 (fr) 2006-05-04 2007-11-15 Pfizer Products Inc. 4-pyrimidine-5-amino-pyrazoles
JP2009537505A (ja) 2006-05-18 2009-10-29 バイエル・ヘルスケア・アクチェンゲゼルシャフト インプリタピドを含む薬学的組成物およびこの薬学的組成物の使用方法
US7691811B2 (en) 2006-05-25 2010-04-06 Bodor Nicholas S Transporter-enhanced corticosteroid activity and methods and compositions for treating dry eye
TWI398252B (zh) 2006-05-26 2013-06-11 Novartis Ag 吡咯并嘧啶化合物及其用途
CN101790527A (zh) 2006-07-20 2010-07-28 凯利普西斯公司 Rho激酶的苯并噻吩抑制剂
WO2008013622A2 (fr) 2006-07-27 2008-01-31 E. I. Du Pont De Nemours And Company Amides azocycliques fongicides
WO2008016123A1 (fr) 2006-08-03 2008-02-07 Takeda Pharmaceutical Company Limited INHIBITEUR DE LA GSK-3β
US8318723B2 (en) 2006-08-16 2012-11-27 Boehringer Ingelheim International Gmbh Pyrazine compounds, their use and methods of preparation
PE20080769A1 (es) 2006-09-08 2008-08-14 Novartis Ag Derivados de biaril-sulfonamida
WO2008035376A2 (fr) 2006-09-19 2008-03-27 Council Of Scientific & Industrial Research Nouvel insert bio-érodable pour applications ophtalmiques et procédé de préparation correspondant
AR063142A1 (es) 2006-10-04 2008-12-30 Pharmacopeia Inc Derivados de 2-(bencimidazolil) purina y purinonas 6-sustituidas utiles como inmunosupresores,y composiciones farmaceuticas que los contienen.
TW200837064A (en) 2006-10-04 2008-09-16 Pharmacopeia Inc 8-substituted 2-(benzimidazolyl)purine derivatives for immunosuppression
US20120225057A1 (en) 2006-10-11 2012-09-06 Deciphera Pharmaceuticals, Llc Methods and compositions for the treatment of myeloproliferative diseases and other proliferative diseases
CA2667487C (fr) 2006-11-06 2017-04-04 Supergen, Inc. Derives d'imidazo[1,2-b]pyridazine et de pyrazolo[1,5-a]pyrimidine et utilisation de ceux-ci comme inhibiteurs de proteines kinases
US20080119496A1 (en) 2006-11-16 2008-05-22 Pharmacopeia Drug Discovery, Inc. 7-Substituted Purine Derivatives for Immunosuppression
KR101588583B1 (ko) 2006-11-22 2016-01-28 인사이트 코포레이션 키나제 억제제로서의 이미다조트리아진 및 이미다조피리미딘
WO2008067119A2 (fr) 2006-11-27 2008-06-05 Smithkline Beecham Corporation Nouveaux composés
NZ577111A (en) 2006-12-15 2012-05-25 Abbott Lab Novel oxadiazole compounds
MX2009006543A (es) 2006-12-20 2009-06-26 Amgen Inc Compuestos heterociclicos y su uso en el tratamiento de la inflamacion, angiogenesis y cancer.
CA2672438A1 (fr) 2006-12-20 2008-07-03 Amgen Inc. Heterocycles substitues et leurs methodes d'utilisation
US8389014B2 (en) 2006-12-22 2013-03-05 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Gel useful for the delivery of ophthalmic drugs
US8513270B2 (en) 2006-12-22 2013-08-20 Incyte Corporation Substituted heterocycles as Janus kinase inhibitors
JP2008179621A (ja) 2006-12-28 2008-08-07 Taisho Pharmaceutical Co Ltd 含窒素飽和複素環化合物
KR20080062876A (ko) 2006-12-29 2008-07-03 주식회사 대웅제약 신규한 항진균성 트리아졸 유도체
WO2008082839A2 (fr) 2006-12-29 2008-07-10 Abbott Laboratories Inhibiteurs de la pim kinase comme agents chimiothérapeutiques destinés à lutter contre le cancer
WO2008082840A1 (fr) 2006-12-29 2008-07-10 Abbott Laboratories Inhibiteurs de la pim kinase utilisés comme agents chimiothérapeutiques contre le cancer
CA2679659C (fr) 2007-03-01 2016-01-19 Novartis Ag Inhibiteurs de pim kinase et procedes de leur utilisation
EP2137184B1 (fr) 2007-04-03 2013-05-08 Array Biopharma, Inc. Composés imidazo[1,2-a]pyridine utilisés comme inhibiteurs des récepteurs à activité tyrosine kinase
GB0709031D0 (en) 2007-05-10 2007-06-20 Sareum Ltd Pharmaceutical compounds
JP5603770B2 (ja) 2007-05-31 2014-10-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｃｒ２受容体拮抗薬およびその使用
GB0710528D0 (en) 2007-06-01 2007-07-11 Glaxo Group Ltd Novel compounds
CL2008001709A1 (es) 2007-06-13 2008-11-03 Incyte Corp Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
MX2009013402A (es) 2007-06-13 2010-02-24 Incyte Corp Sales de inhibidor de janus cinasa (r)-3-(4-(7h-pirrolo[2,3-d]piri midin-4-il)-1h-pirazol-1-il)-3-ciclopentilpropanitrilo.
KR101258316B1 (ko) 2007-07-11 2013-04-30 화이자 인코포레이티드 안구 건조증 치료용 약학 조성물 및 방법
BRPI0815042A2 (pt) 2007-08-01 2015-02-10 Pfizer Compostos de pirazol
WO2009049028A1 (fr) 2007-10-09 2009-04-16 Targegen Inc. Composés de pyrrolopyrimidine et leur utilisation en tant qu'inhibiteurs des janus kinases
US20110263664A1 (en) 2007-11-15 2011-10-27 Musc Foundation For Research Development Inhibitors of PIM-1 Protein Kinases, Compositions and Methods for Treating Prostate Cancer
EA020777B1 (ru) 2007-11-16 2015-01-30 Инсайт Корпорейшн 4-пиразолил-n-арилпиримидин-2-амины, 4-пиразолил-n-пиразолилпиримидин-2-амины и 4-пиразолил-n-пиридилпиримидин-2-амины в качестве ингибиторов киназ janus
GB0723815D0 (en) 2007-12-05 2008-01-16 Glaxo Group Ltd Compounds
PL3133080T3 (pl) 2008-01-18 2018-12-31 Inst Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Nowe cytostatyczne nukleozydy 7-deazapurynowe
US8273744B2 (en) 2008-02-04 2012-09-25 Mercury Therapeutics, Inc. AMPK modulators
PE20091577A1 (es) 2008-03-03 2009-11-05 Novartis Ag Inhibidores de cinasa pim y metodos para su uso
ES2602577T3 (es) 2008-03-11 2017-02-21 Incyte Holdings Corporation Derivados de azetidina y ciclobutano como inhibidores de JAK
BRPI0908906A2 (pt) 2008-03-21 2019-09-24 Novartis Ag compostos heterocíclicos e usos dos mesmos
CN105147608B (zh) 2008-06-26 2019-12-10 安特里奥公司 真皮递送
UY31952A (es) 2008-07-02 2010-01-29 Astrazeneca Ab 5-metilideno-1,3-tiazolidina-2,4-dionas sustituidas como inhibidores de quinasa pim
FR2933409B1 (fr) 2008-07-03 2010-08-27 Centre Nat Rech Scient NOUVEAUX PYRROLO °2,3-a! CARBAZOLES ET LEUR UTILISATION COMME INHIBITEURS DES KINASES PIM
WO2010022081A1 (fr) 2008-08-19 2010-02-25 Array Biopharma Inc. Composés de triazolopyridine comme inhibiteurs des kinases pim
TWI496779B (zh) 2008-08-19 2015-08-21 Array Biopharma Inc 作為ｐｉｍ激酶抑制劑之***吡啶化合物
SI2384326T1 (sl) 2008-08-20 2014-06-30 Zoetis Llc Pirolo(2,3-d)pirimidinske spojine
AU2009289317A1 (en) 2008-09-02 2010-03-11 Novartis Ag Heterocyclic PIM-kinase inhibitors
US8329732B2 (en) 2008-09-02 2012-12-11 Novartis Ag Kinase inhibitors and methods of their use
KR20110058866A (ko) 2008-09-02 2011-06-01 노파르티스 아게 비시클릭 키나제 억제제
CL2009001884A1 (es) 2008-10-02 2010-05-14 Incyte Holdings Corp Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
EP2350054A4 (fr) 2008-10-17 2012-03-28 Merck Canada Inc Dérivés d'azétidine comme inhibiteurs de la stéaroyl-coenzyme a delta-9 désaturase
JOP20190230A1 (ar) 2009-01-15 2017-06-16 Incyte Corp طرق لاصلاح مثبطات انزيم jak و المركبات الوسيطة المتعلقة به
EP2210890A1 (fr) 2009-01-19 2010-07-28 Almirall, S.A. Dérivés d'oxadiazoles en tant qu'agonistes du récepteur S1P1
US8263601B2 (en) 2009-02-27 2012-09-11 Concert Pharmaceuticals, Inc. Deuterium substituted xanthine derivatives
NZ596374A (en) 2009-05-22 2014-01-31 Incyte Corp 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors
AU2010249380B2 (en) 2009-05-22 2015-08-20 Incyte Holdings Corporation N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as Janus kinase inhibitors
UA110324C2 (en) 2009-07-02 2015-12-25 Genentech Inc Jak inhibitory compounds based on pyrazolo pyrimidine
WO2011025685A1 (fr) 2009-08-24 2011-03-03 Merck Sharp & Dohme Corp. L'inhibition de jak bloque les toxicités associées à l'arn d'interférence
TW201111385A (en) 2009-08-27 2011-04-01 Biocryst Pharm Inc Heterocyclic compounds as janus kinase inhibitors
AR078012A1 (es) 2009-09-01 2011-10-05 Incyte Corp Derivados heterociclicos de las pirazol-4-il- pirrolo (2,3-d) pirimidinas como inhibidores de la quinasa janus
EP2475659B1 (fr) 2009-09-08 2015-10-28 F.Hoffmann-La Roche Ag Composés de pyridin-3-yl-carboxamide 4-substitué et procédés d'utilisation
EP2305660A1 (fr) 2009-09-25 2011-04-06 Almirall, S.A. Nouveaux dérivés de thiadiazole
MX2012004180A (es) 2009-10-09 2012-07-17 Incyte Corp Derivados de hidroxil, ceto y glucuronido de 3-(4-7h-pirrolo[2,3-d ]pirimidin-a-il)-1h-pirazol-1-il)-3-ciclopentilpropanonitrilo.
AU2010309882B2 (en) 2009-10-20 2016-01-28 Cellzome Limited Heterocyclyl pyrazolopyrimidine analogues as JAK inhibitors
EP2332917B1 (fr) 2009-11-11 2012-08-01 Sygnis Bioscience GmbH & Co. KG Composés pour l'inhibition de kinase PIM et pour le traitement des tumeurs
CN102740888B (zh) 2009-11-24 2016-10-12 奥尔德生物制药公司 Il-6抗体及其用途
US20130129675A1 (en) 2009-12-04 2013-05-23 Board Of Regents, The University Of Texas System Interferon therapies in combination with blockade of stat3 activation
WO2011086053A1 (fr) 2010-01-12 2011-07-21 F. Hoffmann-La Roche Ag Composés hétérocycliques tricycliques, leurs compositions et procédés d'utilisation
SA111320200B1 (ar) 2010-02-17 2014-02-16 ديبيوفارم اس ايه مركبات ثنائية الحلقة واستخداماتها كمثبطات c-src/jak مزدوجة
BR112012020693B1 (pt) 2010-02-18 2020-05-12 Incyte Holdings Corporation Derivados de ciclobutano e metilciclobutano como inibidores de janus quinase e composição que os compreende
TWI694826B (zh) 2010-03-10 2020-06-01 美商英塞特公司 作為ｊａｋ１抑制劑之哌啶-４-基三亞甲亞胺衍生物
CN102822546B (zh) * 2010-03-30 2015-10-14 Ntn株式会社 滚动轴承
CN102985424B (zh) 2010-04-14 2015-03-11 阵列生物制药公司 5,7-取代的-咪唑并[1,2-c]嘧啶
EP2390252A1 (fr) 2010-05-19 2011-11-30 Almirall, S.A. Nouveaux dérivés de pyrazole
MY161078A (en) 2010-05-21 2017-04-14 Incyte Holdings Corp Topical formulation for a jak inhibitor
US8637529B2 (en) 2010-06-11 2014-01-28 AbbYie Inc. Pyrazolo[3,4-d]pyrimidine compounds
US9351943B2 (en) 2010-07-01 2016-05-31 Matthew T. McLeay Anti-fibroblastic fluorochemical emulsion therapies
US20130237493A1 (en) 2010-09-30 2013-09-12 Portola Pharmaceuticals, Inc. Combination therapy of 4-(cyclopropylamino)-2-(4-(4-(ethylsulfonyl)piperazin-1-yl)phenylamino)pyrimidine-5-carboxamide and fludarabine
EA026201B1 (ru) 2010-11-19 2017-03-31 Инсайт Холдингс Корпорейшн Циклобутилзамещенные производные пирролопиридина и пирролопиримидина как ингибиторы jak
CA2818545C (fr) 2010-11-19 2019-04-16 Incyte Corporation Pyrrolopyridines et pyrrolopyrimidines a substitution heterocyclique utilisees en tant qu'inhibiteurs des jak
SG190950A1 (en) 2010-12-03 2013-07-31 Ym Biosciences Australia Pty Treatment of jak2-mediated conditions
PL2675451T3 (pl) 2011-02-18 2016-05-31 Novartis Pharma Ag Terapia skojarzona z inhibitorem mTOR/JAK
US8691807B2 (en) 2011-06-20 2014-04-08 Incyte Corporation Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors
EP2741747A1 (fr) 2011-08-10 2014-06-18 Novartis Pharma AG Polythérapie par jak p13k/mtor
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) * 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
US9193733B2 (en) 2012-05-18 2015-11-24 Incyte Holdings Corporation Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
US10155987B2 (en) 2012-06-12 2018-12-18 Dana-Farber Cancer Institute, Inc. Methods of predicting resistance to JAK inhibitor therapy
EP2890691B1 (fr) 2012-08-31 2018-04-25 Principia Biopharma Inc. Dérivés de benzimidazole en tant qu'inhibiteurs d'itk
KR20150074193A (ko) 2012-11-01 2015-07-01 인사이트 코포레이션 Jak 억제제로서 트리사이클릭 융합된 티오펜 유도체
ES2880814T3 (es) 2012-11-15 2021-11-25 Incyte Holdings Corp Formas de dosificación de liberación sostenida de ruxolitinib
JP6397831B2 (ja) 2013-03-06 2018-09-26 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｊａｋ阻害剤の製造方法及びその中間体
TWI644671B (zh) * 2013-03-14 2018-12-21 比利時商健生藥品公司 Ｐ２ｘ７調節劑
RS56012B1 (sr) 2013-05-17 2017-09-29 Incyte Corp Derivati bipirazola kao inhibitori jak
EA201690357A1 (ru) 2013-08-07 2016-07-29 Инсайт Корпорейшн Лекарственные формы с замедленным высвобождением для ингибитора jak1
TW201529074A (zh) 2013-08-20 2015-08-01 Incyte Corp 在ｃ-反應蛋白含量較高之實體腫瘤患者中的存活益處
CN106456773A (zh) 2014-02-28 2017-02-22 因赛特公司 用于治疗骨髓增生异常综合征的jak1抑制剂
MA39984B1 (fr) 2014-04-08 2020-12-31 Incyte Corp Traitement d'affections malignes par lymphocytes b par un inhibiteur jak et pi3k combiné
SG11201609016VA (en) 2014-04-30 2016-11-29 Incyte Corp Processes of preparing a jak1 inhibitor and new forms thereto
WO2015184087A2 (fr) 2014-05-28 2015-12-03 Institute For Myeloma & Bone Cancer Research Effets anti-cancéreux d'inhibiteurs de jak2 en combinaison avec des dérivés de thalidomide et des glucocorticoïdes
US9498467B2 (en) 2014-05-30 2016-11-22 Incyte Corporation Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
CN105524067A (zh) * 2014-09-28 2016-04-27 江苏柯菲平医药股份有限公司 4-取代吡咯并[2,3-d]嘧啶化合物及其用途
EP3746429B1 (fr) 2018-01-30 2022-03-09 Incyte Corporation Procédés de préparation de (1-(3-fluoro-2-(trifluorométhyl)isonicotinyl)pipéridine-4-one)

Also Published As

Publication number Publication date
JP2021512163A (ja) 2021-05-13
JP2024023173A (ja) 2024-02-21
IL276302B2 (en) 2023-11-01
KR20200129099A (ko) 2020-11-17
CR20200379A (es) 2021-03-05
PE20211310A1 (es) 2021-07-22
CN112105608B (zh) 2023-07-14
SI3746429T1 (sl) 2023-01-31
WO2019152374A1 (fr) 2019-08-08
DK3746429T3 (da) 2022-05-02
CN112105608A (zh) 2020-12-18
CO2020009994A2 (es) 2020-10-30
PL3746429T3 (pl) 2022-06-20
MD3746429T2 (ro) 2022-08-31
CA3089832A1 (fr) 2019-08-08
ZA202004692B (en) 2021-09-29
PT3746429T (pt) 2022-06-20
TWI797242B (zh) 2023-04-01
IL276302A (en) 2020-09-30
PH12020551145A1 (en) 2021-05-31
IL276302B1 (en) 2023-07-01
EP4086245A1 (fr) 2022-11-09
AU2019213665B2 (en) 2024-06-13
HRP20220510T1 (hr) 2022-05-27
RS63312B1 (sr) 2022-07-29
UA127488C2 (uk) 2023-09-06
CL2020001983A1 (es) 2021-02-19
LT3746429T (lt) 2022-05-10
SG11202007164UA (en) 2020-08-28
US10899736B2 (en) 2021-01-26
TW201940475A (zh) 2019-10-16
AR114810A1 (es) 2020-10-21
US20190233392A1 (en) 2019-08-01
EA202091830A1 (ru) 2020-12-29
MX2020007973A (es) 2020-12-07
EP3746429A1 (fr) 2020-12-09
MA51771B1 (fr) 2022-03-31
EP3746429B1 (fr) 2022-03-09
BR112020015470A2 (pt) 2020-12-08
JP7393348B2 (ja) 2023-12-06
ES2912469T3 (es) 2022-05-26
AU2019213665A1 (en) 2020-08-13

Similar Documents

Publication Publication Date Title
MA51771A (fr) Procédés de préparation de (1-(3-fluoro-2-(trifluorométhyl)isonicotinyl)pipéridine-4-one)
PH12017502090A1 (en) Heterocyclic amides as kinase inhibitors
EA201891024A1 (ru) Соединения-ингибиторы tank-связывающей киназы
DK3340981T3 (da) Aryl, heteroaryl og heterocykliske forbindelser til behandling af medicinske forstyrrelser
DK3359542T3 (da) Spiro[3h-indol-3,2'-pyrrolidin]-2(1h)-on-forbindelser og derivater som mdm2-p53-inhibitorer
BR112018002071A2 (pt) compostos heteroarílicos ou arílicos fundidos bicíclicos
SG11202011513RA (en) Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof
IL247833B (en) 2-(2,4-difluorophenyl)-1,1-difluoro-1-(5-converted-pyridin-2-yl)-3-(1h-tetrazol-1-yl)propan-2-ols and processes for their preparation
SI3448848T1 (sl) Polimorfna oblika N-(6-(2-hidroksipropan-2-il)-2-(2-(metilsulfonil)etil)-2H-indazol-5-il) -6-(trifluormetil)piridin-2-karboksamida
MX2019011789A (es) 2-(2,4-difluorofenil)-1,1-difluoro-1-(5-sustituido-piridin-2-il)- 3-(1h-tetrazol-1-il)propan-2-oles y procesos para su preparacion.
EA201890256A1 (ru) 2-амино-3-фтор-3-(фторметил)-6-метил-6-фенил-3,4,5,6-тетрагидропиридины в качестве ингибиторов bace1
EP3376866A4 (fr) 4-((6-2-(2,4-difluorophényl)-1,1-difluoro-2-yl) propyl)pyridin-3-yl)oxy)benzonitrile et leurs procédés de préparation
DK3436074T3 (da) Thiazolidforbindelser til behandling af virale infektioner
PH12018500736A1 (en) Methods for treating multiple sclerosis using pyrimidine and pyridine compounds with btk inhibitory activity
DK3227273T3 (da) Sammensætninger, som omfatter 2-((1-(2(4-fluorphenyl)-2-oxoethyl)piperidin-4-yl)methyl)isoindolin-1-on, til behanlding af skizofreni
HUE060654T2 (hu) Heterokondelzált piridonvegyületek és azok IDH-gátlóként történõ alkalmazása
PH12020551465A1 (en) Solid forms of substituted 5,6-dihydro-6-phenylbenzo[f]isoquinolin-2-amine compounds
DK3658547T3 (da) Fremgangsmåde til fremstilling af n-(5-(4-(4-formyl-3-phenyl-1h-pyrazol-1-yl)pyrimidin-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamid
DK3765440T3 (da) Fremgangsmåde til fremstilling af n-alkyl-nitratoethylnitraminer
EP3313396A4 (fr) Inhibiteurs de la kinase du récepteur couplé aux protéines g et méthodes d'utilisation de ceux-ci
DK3456712T3 (da) Hidtil ukendte 2,4,6-trisubstitueret S-triazinforbindelse, fremgangsmåde til fremstilling deraf og anvendelse deraf
DK3439641T3 (da) Sammensætninger, kits og fremgangsmåder til opretholselse af øjenlågshygiejne
DK3620452T3 (da) Fremgangsmåde til fremstilling af lenvatinib
DK3423440T3 (da) 5-methyl-6-phenyl-4,5-dihydro-2h-pyridazin-3-on-derivat til behandlingen af hjernetumorer
PE20180503A1 (es) 2-tiopirimidinonas